Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DNDN - Dendreon Corp. -- Ignore unavailable to you. Want to Upgrade?

To: brk who wrote (80)	11/8/2000 12:22:43 PM
From: Elmer	Read Replies (1) \| Respond to of 751

If the results are good from the ASH conference, do not (I repeat) do not sell these shares. I will post up the earlier Mylovenge results from the S-1 filing later in November. If they continue to be strong, just forget you own this because you'll be tempted to sell and kick yourself if you do. Also, the overall NASDAQ composite moves won't matter if the science works. If this works and it can be platformed to a variety of types of cancer, this stock could do what Amgen did. Again, lots of "ifs".